RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Breakthrough designation is pivotalpatience69 wrote: Could not agree more Fred. It is really nice to see all of those potential buyout deals. Or in the case of covid all of those potential vaccine or licensing deals. The fact is that all of these mean squat. Lets face it at this point we do not know where our 1433 lies in the covid study. Is it in animal studies? Is it progressing well or is it in the bottom drawer of someones desk waiting for review. We just dont know virtually anything. The stock price certainly reflects that. Some colour, clarity & clear timelines are all we ask.
From just a few Months back:
“Based on this encouraging data,” stated Arkady Mandel, Theralase’s Interim CEO, “the company intends to move forward in the research, development and commercialization of the Theralase COVID-19 vaccine.” Log 3 99.99% kill rate in vitro, so yes, animal study is next.